<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03599908</url>
  </required_header>
  <id_info>
    <org_study_id>309/12</org_study_id>
    <nct_id>NCT03599908</nct_id>
  </id_info>
  <brief_title>Evaluation and Validation of Novel Diagnostic Tool for Allergists (AbioSCOPE)</brief_title>
  <official_title>Evaluation and Validation of Novel Diagnostic Tool for Allergists (AbioSCOPE) in Volunteer Population With Respiratory Allergies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abionic SA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire Vaudois</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, investigators evaluated for the first time the diagnostic efficacy of&#xD;
      abioSCOPE® versus Phadia Laboratory System as an aid in the diagnosis of allergic diseases.&#xD;
      Investigators targetted the agreement between test results obtained in abioSCOPE® and a&#xD;
      laboratory reference method (Phadia Laboratory System, ThermoFisher Scientific, Uppsala,&#xD;
      Sweden), considered as a quasi-gold standard in IgE (immunoglobulin E) antibody assays.&#xD;
      Investigators also reported the medical decision taken by a panel of allergy experts who had&#xD;
      access to patient history, skin tests and IgE antibody assay, but blinded to the method used,&#xD;
      i,e, the reference method or the abioSCOPE® .&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2013</start_date>
  <completion_date type="Actual">December 21, 2016</completion_date>
  <primary_completion_date type="Actual">November 14, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic agreement between AbioSCOPE and Phadia Laboratory System</measure>
    <time_frame>12 months</time_frame>
    <description>Comparison of the diagnostic agreement obtain went clinical samples are measured with AbioSCOPE or with Phadia Laboratory System</description>
  </primary_outcome>
  <enrollment type="Actual">105</enrollment>
  <condition>Allergic Rhinitis</condition>
  <condition>Asthma</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Venous blood collection prepared to obtain serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients with history of allergic rhinitis and asthma&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects examined at ambulatory medicine medicine center CHUV / PMU and for wich serum&#xD;
             sample is required for the research of specific IgE (allergic patients, allergic&#xD;
             group) or for any other reason (immunological) (non-allergic control patients, control&#xD;
             group)&#xD;
&#xD;
          -  Subjects for which it is expected (allergic group subjects) or who will be asked&#xD;
             (non-allergic control group) to perform a panel of standard prick tests as basic&#xD;
             allergological investigation, including pollen birch, grasses, mites (D pter, D far),&#xD;
             cat dander.&#xD;
&#xD;
          -  Obtain informed consent from each subject before any study procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of positive HIV-1 viremia by the ultra-sensitive method in the 12 months&#xD;
             preceding the study.&#xD;
&#xD;
          -  Use of any investigational or non-registered product (drug or vaccine)&#xD;
&#xD;
          -  Chronic administration (more than 14 days) of immunosuppressive or immunomodulatory&#xD;
             drugs in the 6 months preceding the study for corticosteroids. This means a dose of&#xD;
             Prednisone or equivalent substance greater than or equal to 0.5 mg per kg / day.&#xD;
             Inhaled topical steroids are allowed.&#xD;
&#xD;
          -  Administration of any immunoglobulin, any immunotherapy or administration of some&#xD;
             blood products in the 3 months preceding the study, or planned during the study&#xD;
             period.&#xD;
&#xD;
          -  Any health condition or patient history, in the opinion of the investigator, could&#xD;
             interfere with the evaluation of the study's objectives.&#xD;
&#xD;
          -  Participation in another experimental protocol during the period of the study.&#xD;
&#xD;
          -  Demonstration, confirmation or suspicion of a condition of immunosuppression or&#xD;
             immunodeficiency (including HIV infection) based on medical history and physical&#xD;
             examination (no laboratory test).&#xD;
&#xD;
          -  A family history of congenital or hereditary immunodeficiency.&#xD;
&#xD;
          -  Subjects taking any of the following medications: antihistamines in the week preceding&#xD;
             the consultation, systemic steroids (inhaled or nasal steroids are allowed),&#xD;
             anti-cytokines or cytokines, systemic interferon (injection local interferon α for the&#xD;
             treatment of HPV is allowed) or treated with systemic chemotherapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francois Spertini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire Vaudois</affiliation>
  </overall_official>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 16, 2018</study_first_submitted>
  <study_first_submitted_qc>July 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>July 25, 2018</last_update_submitted>
  <last_update_submitted_qc>July 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Vaudois</investigator_affiliation>
    <investigator_full_name>François Spertini</investigator_full_name>
    <investigator_title>Professor/Doctor</investigator_title>
  </responsible_party>
  <keyword>IgE</keyword>
  <keyword>skin prick tests</keyword>
  <keyword>diagnosis</keyword>
  <keyword>rhinitis</keyword>
  <keyword>asthma</keyword>
  <keyword>allergy</keyword>
  <keyword>laboratory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

